Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer ...

The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world's population and is generally ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

They were treated with a genetically modified HSV-1 in combination with an immunotherapy called nivolumab. The findings, ...

A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with advanced Hodgkin lymphoma.

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved ...

Nivolumab has recently been approved both in combination with fluoropyrimidine- and platinum-based combination chemotherapy and in combination with ipilimumab for the first-line treatment of ...

EFS rate at 18 months was also 20 percentage points higher among the patients who received nivolumab vs placebo (70% vs 50%), and more of the patients randomized to treatment with nivolumab plus ...

Nivolumab-based combinations may therefore "offer clinicians and payers a therapeutic option for previously untreated advanced RCC that may reduce the substantial clinical and economic impacts in ...

Findings also showed at 47 months, nivolumab plus ipilimumab statistically significantly reduced the risk of disease progression or death by 38% vs nivolumab monotherapy (HR, 0.62 [95% CI, 0.48-0. ...